Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
33.9M
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
1.2M
-
Shares change
-
-70.7K
-
Total reported value, excl. options
-
$3.88M
-
Value change
-
-$215K
-
Number of buys
-
5
-
Number of sells
-
-2
-
Price
-
$3.23
Significant Holders of Benitec Biopharma Inc. - Common Stock (BNTC) as of Q4 2023
14 filings reported holding BNTC - Benitec Biopharma Inc. - Common Stock as of Q4 2023.
Benitec Biopharma Inc. - Common Stock (BNTC) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.2M shares
of 33.9M outstanding shares and own 3.54% of the company stock.
Largest 10 shareholders include FRANKLIN RESOURCES INC (588K shares), SUVRETTA CAPITAL MANAGEMENT, LLC (204K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (189K shares), JANUS HENDERSON GROUP PLC (180K shares), VANGUARD GROUP INC (16.7K shares), GEODE CAPITAL MANAGEMENT, LLC (10K shares), MORGAN STANLEY (5.1K shares), Tower Research Capital LLC (TRC) (2.5K shares), UBS Group AG (622 shares), and GAMMA Investing LLC (337 shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.